Ha Jong-Ho, Choi Youn Whan, Moon Ji Eun, Im Soo-Bin, Jeong Je Hoon
Department of Neurosurgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Department Biostatistics, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Korean J Neurotrauma. 2024 Sep 19;20(3):180-190. doi: 10.13004/kjnt.2024.20.e28. eCollection 2024 Sep.
Osteoporosis is one of the most common causes of thoracolumbar compression fractures. Teriparatide is an anabolic agent used to treat osteoporosis. This study aimed to determine whether teriparatide treatment for over 6 months could be effective in patients with osteoporotic thoracolumbar compression fractures.
Between July 2012 and June 2020, we reviewed 50 patients with thoracolumbar osteoporotic compression fractures who could be followed up for more than 1 year. Patients were divided into 3 groups: 11 patients who did not receive teriparatide (Group 0), 19 patients who received teriparatide for less than 5 months (Group 1), and 20 patients who received teriparatide for over 6 months (Group 2). Demographic data, visual analog scale (VAS) scores, and medical histories were reviewed. Radiographs were reviewed to evaluate the vertebral body compression ratio and kyphotic angles.
VAS scores improved in all groups at each time point after injury. Score improvements at 6 months and 1 year between Group 0 and Groups 1 or 2 were significantly different. The compression ratio in all groups increased at each time point after injury, but the differences between Groups 0, 1, and 2 were statistically significant at 3 weeks and 6 months. While the kyphotic angle significantly increased at 1 year in all groups, the differences between the groups at each time point did not reach statistical significance.
Over 6 months of teriparatide treatment had some effects on pain in patients with osteoporotic thoracolumbar compression fractures, but did not prevent the progression of vertebral collapse.
骨质疏松症是胸腰椎压缩性骨折最常见的病因之一。特立帕肽是一种用于治疗骨质疏松症的促合成代谢药物。本研究旨在确定特立帕肽治疗超过6个月对骨质疏松性胸腰椎压缩性骨折患者是否有效。
2012年7月至2020年6月期间，我们回顾性分析了50例胸腰椎骨质疏松性压缩性骨折且随访时间超过1年的患者。患者分为3组：11例未接受特立帕肽治疗的患者（0组），19例接受特立帕肽治疗少于5个月的患者（1组），以及20例接受特立帕肽治疗超过6个月的患者（2组）。回顾了人口统计学数据、视觉模拟评分（VAS）以及病史。通过X线片评估椎体压缩率和后凸角。
所有组在受伤后的每个时间点VAS评分均有所改善。0组与1组或2组在6个月和1年时的评分改善差异有统计学意义。所有组在受伤后的每个时间点椎体压缩率均增加，但0组、1组和2组在3周和6个月时的差异有统计学意义。虽然所有组在1年时后凸角均显著增加，但各时间点组间差异未达到统计学意义。
特立帕肽治疗超过6个月对骨质疏松性胸腰椎压缩性骨折患者的疼痛有一定效果，但不能阻止椎体塌陷的进展。
